AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06184451 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo transcutaneous electrical nerve stimulation
Description: The equipment has a two-phase and pulsed symmetric quadratic waveform. 5x5cm adhesive electrodes will be applied to the lateral and medial edges and superior and inferior to the patella, in a crossed manner, surrounding the region.~The parameters established for the protocol of this study are based on a survey already carried out, with continuous pulse mode, frequency of 150Hz, duration of 150us, and amplitude varying from 1-60mA or more as long as tolerated by the study participant, without causing pain. To do this, the device will only be turned on during the first minute of therapeutic exercises. The same TENS parameters as the experimental group will be applied for this.
Study NCT06673602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCYC+Conventional treatment
Description: Conventional treatment combined with oral administration of FCYC (four capsules, three times a day, orally) for a 12-week course of treatment.
Study NCT06673602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: The control group will receive the current gold standard treatment for ICH according to the guidelines (AHA/ASA 2022). This involves blood pressure and care.
Study NCT05394779 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DTXO APP
Description: DTXO is an investigational therapeutic intervention (Digital Therapeutics - DTx) for obese patients, under clinical validation with a randomized and placebo-controlled clinical trial for confirmatory purposes. It is intended to improve weight loss, weight-loss maintenance, and overall health in patients with obesity by increasing their self-engagement, self-monitoring and adherence to dietary/exercise and behavioral programs. The App integrates different non-pharmacological approaches, engaging the patient through monitoring of her/his non-vital parameters, monitoring of patient diet and exercise, monitoring of patient psychological status, prescription of exercise and diet in a weight-loss program.
Study NCT05394779 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO APP - Control group
Description: The placebo App will include only the non-medical modules of the digital therapy and has been introduced to make the experience of subjects in the control arm more similar to that of subjects in the experimental arm; moreover, data collection through the placebo app (questionnaires) will streamline the data collection process, avoiding manual data entry and reducing the possibility of entry errors.
Study NCT04755530 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Regular whole milk
Description: 400 g/day of regular whole milk
Study NCT04755530 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yogurt with live bacteria
Description: 400 g/day of yogurt with live bacteria
Study NCT04755530 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yogurt with inactivated bacteria
Description: 400 g/day of yogurt with inactivated bacteria
Study NCT04755530 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acidified whole milk
Description: 400 g/day of yogurt with acidified whole milk
Study NCT06100705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Cypionate
Description: Testosterone Cypionate is an androgen and anabolic steroid medication which is used mainly in the treatment of low testosterone levels in men.
Study NCT06516939 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bovine Basic Gel
Description: Bovine Basic Gel
Study NCT04778267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: We hypothesize that combined ESPB and PIPB are as effective as TPVB in controlling perioperative pain in patients undergoing modified radical mastectomy (MRM) with lesser complications using bupivacaine hydrocloride
Study NCT04778267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: We hypothesize that combined ESPB and PIPB are as effective as TPVB in controlling perioperative pain in patients undergoing modified radical mastectomy (MRM) with lesser complications using bupivacaine hydrocloride
Study NCT04778267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone phosphate
Description: used as additive to bupivacaine
Study NCT04778267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone phosphate
Description: used as additive to bupivacaine
Study NCT05274113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4mg
Description: 4 mg of Dexamethasone will be given before surgery
Study NCT04862494 — intervention group
Intervention type: OTHER
Intervention: clinical surveillance
Description: regular clinical follow up including chest X-rays, pulmonary investigations, etc...
Study NCT06100705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T
Description: Sipuleucel-T is the first FDA-approved immunotherapy in treatment of mCRPC. It is a therapeutic cancer vaccine composed of activated autologous dendritic cells loaded with an engineered fusion protein of prostatic acid phosphatase and granulocyte-macrophage colony-stimulating factor, PAP-GMCSF, also called PA2024. This cellular product is prepared in three steps: (1) leukapheresis to isolate CD54+ dendritic cells, (2) the cells and harvested and cultured with PA2024 ex vivo, and (3) re-infusion of the activated DC into the original patient. The preparation and administration of this autologous cellular product are done every 2 weeks for a total of three infusions and is designed to elicit an immune response to prostatic acid phosphatase.
Study NCT04862494 — intervention group
Intervention type: PROCEDURE
Intervention: diaphragmatic plication
Description: plication of a hemidiaphragm, performed via laparoscopy, thoracoscopy (including robot-assisted surgery), or classical thoracotomy
Study NCT04120987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lifitegrast 5% Ophthalmic Solution
Description: BID OU
Study NCT05858931 — intervention group
Intervention type: PROCEDURE
Intervention: vaginal repair
Description: vaginal repair
Study NCT05774444 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Krill oil
Description: Krill oil will be supplemented to see if they can gain strength and/or muscle mass following supplementation.
Study NCT05774444 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Krill protein
Description: Krill protein will be given to the participant following a resistance exercise bout.
Study NCT05774444 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vegetable oil
Description: This will be the control against the Krill oil
Study NCT05774444 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vegetable oil
Description: This will be the control against the Krill oil
Study NCT05774444 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate
Description: This will be the control for the Krill protein
Study NCT05774444 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Carbohydrate
Description: This will be the control for the Krill protein
Study NCT05734924 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: low Frequency High Intensity magnetic therapy
Description: low Frequency High Intensity magnetic therapy with frequency 50 Hz and high intensity 60mT
Study NCT05734924 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low Frequency High Intensity magnetic therapy
Description: low Frequency High Intensity magnetic therapy with frequency 50 Hz and high intensity 60mT
Study NCT06062212 — intervention group
Intervention type: PROCEDURE
Intervention: Transpulmonary pressure
Description: Use transpulmonary pressure to guide ventilator setting in ECMO for severe ARDS patients.
Study NCT05304663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onfekafusp alfa
Description: Patients will be treated with 10 µg/kg L19TNF on Days 1, 3 and 5, and on Days 22, 24 and 26
Study NCT05304663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Arm 1: Patients will be treated in escalating cohorts of 6 patients with lomustine at different doses (60 mg/m2 and 75 mg/m2) on Day 1 and Day 22 (taken in the evening after L19TNF infusion) of a 42-day cycle for up to a maximum of 6 cycles.~Arm 2: Patients will be treated in escalating cohorts of 6 patients with lomustine at different doses (90 mg/m2 and 110 mg/m2) on Day 5 (in the evening after infusion of L19TNF) of a 42-day cycle for up to a maximum of 6 cycles.
Study NCT06134466 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid Extensively hydrolyzed cow's milk protein infant formula
Description: Liquid Investigational Formula (Extensively hydrolyzed cow's milk protein infant formula) 2.8 g protein/100 kcal
Study NCT04704037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guideline implementation tool
Description: Family physicians will receive a tailored letter with their patient's mental health screening test results and associated mental health treatment recommendations from the Ontario Neurotrauma Foundation guidelines, as well as a list of mental health treatment resources. In addition, the patient will receive a written information package about mental health problems after mTBI and treatment options to discuss with their family physician.
Study NCT04704037 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Generic information about concussion management
Description: Family physicians will receive a generic letter drawing their attention to Canadian clinical practice guidelines for mild Traumatic Brain Injury (developed by the Ontario Neurotrauma Foundation). Patients will receive instructions about how to access generic education materials about mTBI (from concussion.vch.ca/), which they should have received anyway as part of usual care.
Study NCT05573854 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gastric emptying after an oral supplement containing carbohydrates and whey protein
Description: Ingestion of an oral supplement containing carbohydrates and whey protein
Study NCT06557200 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Infant- parents support
Description: A virtual and in-person, personal and group-based intervention will be delivered-educational information on infant behavior and changes in interpersonal dynamics associated with parenting. Modules aimed at understanding and managing infant behavior include information on infant temperament. Personal support will be provided by face-to-face education and WhatsApp messages and videos. Group support will be provided by mothers and their partners or a support person group discussion.
Study NCT05901428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel is a taxoid antineoplastic agent used in the treatment of breast cancer
Study NCT05901428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel is a taxoid antineoplastic agent used in the treatment of breast cancer
Study NCT05573854 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Overnight Fast
Description: Residual Gastric Volume assessed by MRI after overnight fast (8h)
Study NCT03180450 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)
Description: Allogeneic umbilical cord mesenchymal stem cells will transfusion by intravenous transplantation.
Study NCT03180450 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: conventional treatment
Description: The drug and usage will be determined based on patient's condition, including milrinone, furosemide, beta-blocker blues, Angiotensin-Converting Enzyme Inhibitors (ACEI), angiotension receptor blocker (ARB), or antiplatelet aggregation etc.
Study NCT03180450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conventional treatment
Description: The drug and usage will be determined based on patient's condition, including milrinone, furosemide, beta-blocker blues, Angiotensin-Converting Enzyme Inhibitors (ACEI), angiotension receptor blocker (ARB), or antiplatelet aggregation etc.
Study NCT04908644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MS-20 oral solution
Description: Fermented soybean extract MicrSoy-20(MS-20), which uses a variety of lactic acid bacteria and yeasts to metabolize organic soybeans
Study NCT04908644 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04955548 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arthroscopic micro-fracture with autologous adipose gel
Description: Fully cut the adipose tissue taken out under the arthroscopy, transfer the cut adipose tissue to a syringe connected with a double pass, push back and forth through the syringe to physically emulsify the adipose, and centrifuge to obtain the autologous adipose gel, and inject it into the lesion
Study NCT05570188 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19 UCAR-NK cells
Description: Enrolled participants are chosen to receive one of three different dose levels of U-CAR-NK cells:~Dose level one: 5-10×10\^6/kg; Dose level two:1-2×10\^7/kg; Dose level three:2-5×10\^7/kg.
Study NCT04242264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% Sterile Normal Saline, USP
Study NCT05274113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ultrasound guided supraclavicular block with ropivacaine will be given to patients before surgery
Study NCT04242264 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Sterile Normal Saline, USP
Study NCT04242264 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella sonnei strain 53G
Description: 1.5 x 10\^3 Colony Forming Units (cfu) Shigella sonnei 53G, a virulent strain of wildtype Shigella sonnei
Study NCT04242264 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Shigella sonnei strain 53G
Description: 1.5 x 10\^3 Colony Forming Units (cfu) Shigella sonnei 53G, a virulent strain of wildtype Shigella sonnei
Study NCT04242264 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WRSs2
Description: 10\^6 Colony Forming Units (cfu) dose of an oral live-attenuated Shigella sonnei vaccine candidate derived from a virulent S. sonnei strain Moseley (WRSs2)-a live, attenuated vaccine that has been manufactured under cGMP conditions at the WRAIR PBF
Study NCT06122896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening Blood Tests
Description: Carbohydrate antigen (CA) 19-9, Hemoglobin A1C (HbA1c), and Fasting blood glucose (FBG) per standard-of-care.
Study NCT06122896 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Endoscopic Ultrasound
Description: Annually and per National Comprehensive Cancer Network Guidelines (NCCN) guidelines.
Study NCT06122896 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Annually and per National Comprehensive Cancer Network Guidelines (NCCN) guidelines.
Study NCT06122896 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Cholangiopancreatography
Description: Annually and per National Comprehensive Cancer Network Guidelines (NCCN) guidelines.
Study NCT05494502 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: Prior to general anesthesia, ultrasound guided erector spinae plane block (ESPB; performed with 0.5% ropivacaine 35 ml with dexmedetomidine 1 microgram/kg) is performed at T2 level (15 ml) and T4 level (20 ml).
Study NCT05494502 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: General anesthesia alone.
Study NCT04955548 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthroscopic micro-fracture
Description: Surgeons routinely perform international standard micro-fracture surgery to repair cartilage damage
Study NCT05253313 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI scan
Description: Patients will be randomized to a pre-operative scan or not. The MRI scan will evaluate the local extent of the tumor and especially focus on identifying possible liver metastases unseen on the CT-scan.
Study NCT05702307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose as reference food
Description: Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g glucose diluted in 300ml water, tested three times, in different visits, within 5-10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
Study NCT05702307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tagliatella control
Description: Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from tagliatella control, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
Study NCT05702307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5% sunflower tagliatella
Description: Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from 5% sunflower tagliatella, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
Study NCT05702307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 16% sunflower tagliatella
Description: Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from 16% sunflower tagliatella, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
Study NCT05702307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 16% sunflower penne
Description: Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from 16% sunflower penne, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and samples from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
Study NCT05702307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 16% sunflower fusilli
Description: Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from 16% sunflower fusilli, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
Study NCT01567683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod (topical use)
Study NCT04882449 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bodyport Scale
Description: The Bodyport scale is capable of measuring key HF parameters of congestion and cardiac perfusion on a regular basis in a patient's home. These data will be combined into a composite index that may be used to identify patients at increased risk for decompensation, inform the reason for their decline, and offer the possibility to remotely optimize therapy to prevent further worsening HF.
Study NCT05193188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride
Description: Anlotinib 12mg per person per day, continuous medication for 2 weeks and 1 week off, 3 weeks 1 cycle, until disease progression or intolerable toxicity
Study NCT05193188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anlotinib hydrochloride
Description: Anlotinib 12mg per person per day, continuous medication for 2 weeks and 1 week off, 3 weeks 1 cycle, until disease progression or intolerable toxicity
Study NCT05193188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: Intravenous injection, once every 3 weeks, until the disease progression or intolerable toxicity
Study NCT06450639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satralizumab
Description: Satralizumab will be administered SC in the abdominal or femoral region on Day 1, Weeks 2 and 4 (loading doses) and then Q4W from Weeks 8 to 104 (maintenance doses) until the study completion visit.
Study NCT05479409 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiotherapy
Description: radiation therapy combined with chemotherapy prior to surgery
Study NCT04886999 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exploratory study on patient's perception of Asthma symptoms
Description: To assess the perception of symptoms and the psychopharmacological aspects in patients with moderate to severe asthma comparing two inhalers of CHF1535 100/6 µg pMDI
Study NCT05085795 — intervention group
Intervention type: DEVICE
Intervention: Impulse Oscillometer
Description: The tremoFlo C-100 Airwave Oscillometry System is intended to measure respiratory system impedance using the Forced Oscillation Technique (FOT).
Study NCT05149729 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shortened hip arthroplasty
Description: Crowe type 3 and 4 patients who underwent shortened hip prosthesis
Study NCT04886999 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exploratory study on patient's perception of Asthma symptoms
Description: To assess the perception of symptoms and the psychopharmacological aspects in patients with moderate to severe asthma comparing two inhalers of CHF1535 100/6 µg pMDI